{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"100"},{"groupId":"OG001","value":"98.2"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"5"}],"units":"Participants"}],"description":"Adherence reported as a percentage based on number of doses of study drug taken divided by the expected number of doses of study drug expected to be taken for the study duration.","groups":[{"description":"Patients receive glutamine PO BID. Courses repeat every 28 days for 4 months in the absence of disease progression or unacceptable toxicity.\n\nglutamine: Dose of 15 grams twice times daily (to equal 30 grams a day) for a period of 4 months.\n\nquality-of-life assessment: Ancillary studies","id":"OG000","title":"Arm I (Preventative Nutritional Supplementation)"},{"description":"Patients receive placebo PO BID. Courses repeat every 28 days for 4 months in the absence of disease progression or unacceptable toxicity.\n\nquality-of-life assessment: Ancillary studies\n\nplacebo: Given PO","id":"OG001","title":"Arm II (Placebo)"}],"paramType":"NUMBER","populationDescription":"All patients enrolled in study and given treatment","reportingStatus":"POSTED","timeFrame":"Up to 4 months","title":"Adherence to Bortezomib Treatment","type":"SECONDARY","unitOfMeasure":"% of doses taken"}